Co-Authors
This is a "connection" page, showing publications co-authored by SANKAR NAVANEETHAN and MICHAEL HOLLIDAY.
Connection Strength
4.046
-
Impact of SGLT2 Inhibitors on Glomerular Filtration in Type 1 Diabetes. J Clin Endocrinol Metab. 2026 Jun 17; 111(7):e1912-e1913.
Score: 0.986
-
Expanding Evidence for Glucagon-Like Peptide-1 Receptor Agonists in Those with Diabetes and Kidney Disease. Clin J Am Soc Nephrol. 2026 Apr 09.
Score: 0.973
-
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2024 05 01; 33(3):331-336.
Score: 0.840
-
Editorial: Advancements in the management of kidney disease and electrolyte derangements. Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):395-398.
Score: 0.758
-
Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors. Curr Opin Nephrol Hypertens. 2026 Sep 01; 35(5):498-503.
Score: 0.246
-
Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease. Int J Nephrol Renovasc Dis. 2026; 19:522424.
Score: 0.243